Akorn to Acquire Hi-Tech Pharmacal - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Akorn to Acquire Hi-Tech Pharmacal

The specialty pharmaceutical companies Akorn and Hi-Tech Pharmacal have formed an agreement under which Akorn will acquire Hi-Tech for $640 million in cash. The deal, which is subject to customary closing conditions, is scheduled to close in the first quarter of 2014. The combined company will have sales in excess of $500 million, according to an Akorn press statement.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing, and marketing generic and branded prescription and over-the-counter (OTC) products. Hi-Tech specializes in difficult-to-manufacture liquid and semisolid dosage forms and produces and markets a range of oral solutions and suspensions as well as topical ointments and creams, nasal sprays, otics, sterile ophthalmics, sterile ointments, and gels products.

The acquisition strengthens Akorn’s position in generic ophthalmic drugs and also broadens its product offering to include other niche dosage forms such as oral liquids, topical creams and ointments, nasal sprays, and otics. The deal also enhances Akorn’s retail presence in both prescription and OTC products. Akorn says it plans to capitalize on the manufacturing capabilities of Hi-Tech to further expand its presence in the private-label OTC business. On a product basis, Akorn currently has 57 abbreviated new drug applications (ANDAs) filed with FDA, and Hi-Tech has filed 18 ANDAs.

Akorn expects to achieve between $15 million and $20 million in annual run-rate synergies within 12 months of close.

Source: Akorn


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here